Compass Pathways' ADRs Tumble on Results for Treatment Using Psychedelic
Markets,Psychedelics,Banking and Finance
American depository receipts of Compass Pathways dropped after trial results for a formulation using the psychedelic psilocybin, designed to help people with treatment-resistant depression, disappointed investors. The ADRs fell 46% to $2.50 on Monday. They are down 60% in the past 12 months. Compass Pathways said before the open that a single dose of 25 milligrams of COMP360 showed a mean treatment difference of -3.6 points compared to a placebo at week six of a Phase 3 trial. The results mark weaker efficacy at week six than the formulation's previous...
Related Coverage
AllSides Picks
Red Blue Translator
Great Depression (The)
Headline Roundup
Could There Be More Behind Jensen Huang's Resignation Than Extramarital Affairs?
November 15th, 2026
Headline Roundup
Trump, Putin and Xi Plan Historic Three-Way Summit in China
November 14th, 2026
The Insight
Is America’s homelessness crisis improving?
AllSides Staff
November 13th, 2026